Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

Head Lice Infestation Clinical Trial

Official title:

A Randomized, Double-blind, Multicenter, Vehicle-controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02062060
• Other study ID #: Ha03-002
• Status: Completed
• Phase: Phase 3
• Start date: February 2014
• Est. completion date: August 2014

Study information

• Verified date: May 2020
• Source: Dr. Reddy's Laboratories Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Purpose of this study is to evaluate the efficacy of at-home administration of a single application of abametapir lotion 0.74% w/w for the treatment of head lice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 325
• Est. completion date: August 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

1. Male or female, aged six months of age or older.

2. Is in good general health based on medical history.

3. Has active head lice infestation at Screening as determined by a trained evaluator with the exception of the male head of household who may self-assess as being lice-free. Active head lice infestation is defined as at least three live lice for the index subject and at least one live louse for the other household members.

4. The subject and/or their caregiver is physically able and willing to apply the Investigational Product at home.

5. Belongs to a household with an eligible index subject with active head lice infestation.

6. Agrees to an examination for head lice and to all visits and procedures throughout the study.

7. Has signed an informed consent and/or assent form.

Exclusion Criteria:

1. Had treatment (over-the-counter), home remedy or prescription medication) for head lice within 14 days prior to Day 0.

2. Intends to use any other form of lice treatment from Day 0 through the Day 14 visit, unless provided as rescue therapy to this Protocol.

3. Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as rescue therapy to this Protocol.

4. Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling from Day 0 through the Day 14 visit.

5. Has a household member(s) who is infested with lice but is not willing or not eligible for enrollment.

6. Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.

7. Has visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or Sponsor, will interfere with safety and/or efficacy evaluations.

8. Has eczema or atopic dermatitis of skin/scalp.

9. Has had a prior reaction to Nix® or products containing permethrin.

10. Receiving systemic or topical medication, which in the opinion of the Investigator, may compromise the integrity of the safety and/or efficacy assessments.

11. Has received an investigational agent within 30 days prior to Day 0.

12. Does not have a known household affiliation with the household members (i.e., does not stay in one household consistently, or sleeps at one place for several nights and then at another place or location).

Related Conditions & MeSH terms

• Head Lice Infestation
• Lice Infestations
• Parasitic Diseases

Intervention

Drug:
• Abametapir Lotion 0.74% w/w

• Vehicle Lotion

Locations

Country	Name	City	State
United States	Haywood Pediatric	Clyde	North Carolina
United States	Wee Care Pediatrics	Layton	Utah
United States	Axis Clinical Trials	Los Angeles	California
United States	LSRN Research	Nashville	Tennessee
United States	Spence Medical Reserach	Picayune	Mississippi
United States	Radiant Reserach	Pinellas Park	Florida
United States	Cactus Kids Pediatrics	Yuma	Arizona

Sponsors (3)

Lead Sponsor	Collaborator
Dr. Reddy's Laboratories Limited	Accelovance, Syneos Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of index subjects who are lice-free at all follow-up visits through to the Day 14 visit.	The outcome is measured by lice evaluations performed by trained lice evaluator from baseline through follow up visits.	14 days